<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608851</url>
  </required_header>
  <id_info>
    <org_study_id>OYS_Tapiainen_002</org_study_id>
    <nct_id>NCT04608851</nct_id>
  </id_info>
  <brief_title>Preventing Urinary Tract Infections With E. Coli Nissle:</brief_title>
  <acronym>FinNissle</acronym>
  <official_title>Preventing Urinary Tract Infections in Infants and Young Children With Probiotic E. Coli Nissle:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urinary tract infections (UTIs) account for 5-14% of pediatric emergency department visits&#xD;
      annually. At the moment, up to one third of children suffering of acute (UTI) will have a new&#xD;
      infection and there is a lack of effective methods for preventing secondary UTIs in young&#xD;
      children. Majority of UTIs in children are caused by intestinal bacteria of the patient,&#xD;
      mainly E. coli that colonizes gut of the patient. E. coli Nissle is a probiotic strain that&#xD;
      has been used successfully for treating acute gastrointestinal infections in children. The&#xD;
      strain has also been proved to be safe for infants and young children. E. coli Nissle could&#xD;
      be a potential solution for preventing recurrent urinary tract infections in children as it&#xD;
      competes with pathogenic bacteria that usually cause UTIs in children.&#xD;
&#xD;
      The aim of this study is to evaluate efficacy of E. coli Nissle strain in secondary&#xD;
      prevention of urinary tract infections in young children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to asses efficacy of E. coli Nissle strain in prevention of recurrent UTIs in&#xD;
      children, we aim to conduct randomized, placebo controlled and double blinded clinical trial.&#xD;
      We are going to recruit children who are suffering the first urinary tract infection of their&#xD;
      life. The UTI will be treated by normal clinical recommendations decided by treating&#xD;
      physician. Intervention will start on the day following the last day of the antimicrobial&#xD;
      course.&#xD;
&#xD;
      The intervention will last for 15 days and the study participants will receive either&#xD;
      intervention drug or placebo. Intervention drug contains 10 E8 CFU/ml of E. coli Nissle&#xD;
      strain and will be administered as dose of 1 ml of oral suspension once daily for children&#xD;
      aged under one year and twice daily for children aged more than one year.&#xD;
&#xD;
      The study patients will be monitored by monthly electronic surveys for six months after the&#xD;
      intervention in order to measure proportion of the children who will have a new UTI during&#xD;
      the follow up. We are also going to record possible adverse effects in both study groups.&#xD;
      Also use of antimicrobial medication due to any reason will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double Blinded, Placebo controlled and randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The intervention drug or placebo will be given to participants in closed boxes without any labels. Appearance and dosing of the products will be similar. Investigators will not handle the boxes or study products.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of urinary tract infections</measure>
    <time_frame>Six months from study entry</time_frame>
    <description>Proportion of the study patient who will have at least one bacterial culture confirmed urinary tract infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of urinary tract infections</measure>
    <time_frame>Six months from study entry</time_frame>
    <description>Number of bacterial culture confirmed urinary tract infections per person years at risk (PYR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization day due to bacterial culture confirmed urinary tract infection</measure>
    <time_frame>Six months from study entry</time_frame>
    <description>Number of days spent in the hospital during follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial treatment days for suspected or confirmed urinary tract infection</measure>
    <time_frame>Six months, starting after the initial treatment at study entry has ended</time_frame>
    <description>Number of days when study patient has received antimicrobial treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stomach pain</measure>
    <time_frame>Six months from study entry</time_frame>
    <description>Number of days with stomach pain reported by families during follow up at web-based surveys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhea</measure>
    <time_frame>Six months from study entry</time_frame>
    <description>Number of days with diarrhea reported by families during follow up at web-based survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial treatment days for any indication</measure>
    <time_frame>Six months, starting after the initial treatment at study entry has ended</time_frame>
    <description>Number of days when study patient has received antimicrobial treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">530</enrollment>
  <condition>Urinary Tract Infections in Children</condition>
  <condition>Secondary Prevention</condition>
  <arm_group>
    <arm_group_label>Nissle group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral suspension containing 10 E8 CFU/ml of E coli Nissle. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention will start on the day following the ending of the antimicrobial treatment of the UTI. Patients will receive 1 ml of oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g. Patients under one year of age will receive one daily dose and patients aged more than one year will receive a dose twice daily. Intervention will last for 30 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E. coli Nissle</intervention_name>
    <description>1 ml of oral suspension containing 10 E8 CFU /ml of E. coli Nissle strain</description>
    <arm_group_label>Nissle group</arm_group_label>
    <other_name>Mutaflor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>1 ml oral syrup consisting of Saccharum 630 mg/g and Aqua purificata 370 mg/g.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children who suffer of the first urinary tract infection of their life defined as&#xD;
             pyuria, presence of symptoms (fever or focal symptom), no other explanation for&#xD;
             infection, bacterial culture positive or culture result pending&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preterm birth, gestational age less than 35 weeks&#xD;
&#xD;
          -  Signs of life-threatening infection (such as meningitis)&#xD;
&#xD;
          -  Detected anomaly in urinary tract&#xD;
&#xD;
          -  Primary immunodeficiency&#xD;
&#xD;
          -  Detected anomaly of GE tract&#xD;
&#xD;
          -  Ongoing antimicrobial prophylaxis&#xD;
&#xD;
          -  Hospital-acquired infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terhi Tapiainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oulu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Terhi Tapiainen</last_name>
    <phone>+35883155185</phone>
    <email>terhi.tapiainen@oulu.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harri Saxen, MD, PhD</last_name>
      <email>harri.saxen@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Tea Nieminen, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marjo Renko, MD, Phd</last_name>
      <email>marjo.renko@uef.fi</email>
    </contact>
    <investigator>
      <last_name>Katri Backman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Päivi Kallunki-Saesmaa, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <zip>90014</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terhi Tapiainen, MD, PhD</last_name>
      <phone>+358-8-315 5185</phone>
      <email>terhi.tapiainen@oulu.fi</email>
    </contact>
    <contact_backup>
      <last_name>Niko Paalanne, MD, PhD</last_name>
      <phone>+358-8-315-8427</phone>
      <email>niko.paalanne@oulu.fi</email>
    </contact_backup>
    <investigator>
      <last_name>Terhi Tapiainen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikael Hakkola, BM</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Niko Paalanne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kimmo Halt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tytti Pokka, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulla Koskela, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Merja Helminen, MD, PhD</last_name>
      <email>merja.helminen@pshp.fi</email>
    </contact>
    <investigator>
      <last_name>Sari Törmänen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ville Peltola, MD, PhD</last_name>
      <email>ville.peltola@utu.fi</email>
    </contact>
    <investigator>
      <last_name>Lauri Ivaska, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>January 18, 2021</last_update_submitted>
  <last_update_submitted_qc>January 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Oulu</investigator_affiliation>
    <investigator_full_name>Terhi Tapiainen</investigator_full_name>
    <investigator_title>Adjunct Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Urinary Tract Infections</keyword>
  <keyword>E. coli</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>IPD will be shared after reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

